Plain-English translation of NCT07131514 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether HRS-4642, combined with two existing chemotherapy drugs and another immunotherapy medication, can help treat pancreatic cancer. The study is for patients whose cancer can potentially be removed with surgery. You would receive this medication combination both before surgery (to shrink the tumor) and after surgery (to help prevent cancer from coming back).
Pancreatic cancer is a serious disease, and current treatments don't work well enough for all patients. Researchers are testing this new medication combination to see if it can be more effective, either by shrinking tumors before surgery or by reducing the risk of cancer returning afterward.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination in cycles before your surgery to shrink the tumor, then undergo surgery to remove it, and then continue the medication combination afterward. The exact schedule and number of visits would depend on how you respond to treatment and any side effects you experience. This is a single-center study at Ruijin Hospital, so all visits would take place there.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China